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Although episomal vectors are commonly transported into cells by electroporation, a number of
electroporation-derived problems have led to the search for alternative transfection protocols, such as
the use of transfection reagents, which are inexpensive and easy to handle. Polyplex-mediated transport
of episomal vectors into the cytoplasm has been conducted successfully in immortalized cell lines, but no
report exists of successful transfection of primary cells using this method. Accordingly, we sought to
optimize the conditions for polyplex-mediated transfection for effective delivery of episomal vectors into
the cytoplasm of primary mouse embryonic ﬁbroblasts. Episomal vectors were complexed with the
commercially available transfection reagents Lipofectamine 2000, FuGEND HD and jetPEI. The ratio of
transfection reagent to episomal vectors was varied, and the subsequent transfection efﬁciency and
cytotoxicity of the complexes were analyzed using ﬂow cytometry and trypan blue exclusion assay,
respectively. No cytotoxicity and the highest transfection yield were observed when the ratio of trans-
fection reagent to episomal vector was 4 (v/wt) in the cases of Lipofectamine 2000 and FuGENE HD, and
2 in the case of jetPEI. Of the three transfection reagents tested, jetPEI showed the highest transfection
efﬁciency without any cytotoxicity. Thus, we conﬁrmed that the transfection reagent jetPEI could be used
to effectively deliver episomal vectors into primary cells without electroporation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Various gene delivery systems have been developed to intro-
duce useful genes into cells. Virus-mediated gene delivery systems
are generally preferred because of their high transfection efﬁciency
and simple mechanism of infection. However, viral vectors are
randomly integrated into host genomes [1e3], and unexpected
integrations may cause abnormal immunogenic response [4e6]
and mutagenesis [7,8]. Accordingly, non-integrating transfection
systems are desired to overcome such problems.
One non-integrating transfection system is the oriP/EBNA1
episomal vector, based on the EpsteineBarr virus nuclear antigen 1.iomodulation, Department of
l Science, Kangwon National
01, South Korea. Fax: þ82 33
Inc. This is an open access article uBeing an episomal vector, it undergoes one replication per cell cycle
and is segregated into daughter cells without any integration into
the cell genome [9e12], thusmaking it possible to isolate the vector
from target cells through culturing alone, without any drug selec-
tion [13,14]. For this reason, the vector has been widely used for
gene therapy [15] and gene expression in mammalian cells [16].
Generally, the transportation of episomal vectors into the
cytoplasm of target cells is done via electroporation, which uses
electric pulses to create transient pores in a plasma membrane,
through which transgenes may directly enter the cytoplasm.
A major advantage of this method is its versatility, as the parame-
ters of electroporation can be effectively optimized for the type [17]
and size [18] of molecule to be taken up, the type of cell [19], its
status in the cell cycle [20], etc. Thus, electroporation has been used
effectively for gene delivery both in vitro and in vivo [21,22].
However, signiﬁcant drawbacks of the method include the expense
of the equipment [23], potential cell death [24], imbalance of cell
homeostasis [25], and potentially permanent permeabilization of
the plasma membrane [26].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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complexed with transfection reagents to facilitate transport of the
vectors into the cytoplasm without need of electroporation. While
this method was successful in cancerous cell lines [10,27], there are
no reports of successful delivery into primary cells obtained from
fresh tissue. Therefore, in this study we have identiﬁed some
potential commercial transfection reagentsdwhich are inexpen-
sive, involve simple handling, and show low toxicity and immu-
nogenicitydfor transport of episomal vectors into primary cells,
and we evaluated their cytotoxicity and transfection efﬁciency.
2. Materials and methods
2.1. Animals
Mouse embryonic ﬁbroblasts (MEFs) were obtained from the
fetuses of a 13.5-day pregnant ICR mouse (DBL, Eumseong, Korea).
All housing and handling of animals and the experimental pro-
cedures were approved by the Institutional Animal Care and Use
Committee (IACUC) of Kangwon National University (IACUC
approval No. KW-140904-1). The procedures were carried out in
accordance with the Animal Care and Use Guidelines of Kangwon
National University.
2.2. Preparation of primary MEFs
The pregnant mouse was sacriﬁced by cervical dislocation, and
the separated uteri were placed in a petri dish containing Dulbec-
co's phosphate-buffered saline (DPBS; Welgene Inc., Daegu, Korea).
The fetuses were isolated from the uteri and transferred to a petri
dish containing fresh DPBS. To prevent contamination by other cell
types, the heads, legs, tails, and diverse organs were dissected from
the fetuses by insulin syringe under a stereomicroscope. The
remaining fetal tissue was minced ﬁnely using a sterile razor blade,
digested with 0.25% trypsin-EDTA (Welgene) for 10 min at 37 C in
an incubator, and then ﬁltered through a 70-mm nylon mesh (SPL,
Pocheon, Korea). Non-digested ﬁbroblasts remaining on the mesh
were discarded. The ﬁltered and dissociated MEFs were washed
twice in a basic medium composed of Dulbecco's modiﬁed Eagle's
medium (DMEM; Welgene), supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS; Welgene) and 1% (v/v)
antibiotic-antimycotic (Welgene). The washed MEFs were then
seeded on a 100-mm culture dish in the basic medium and incu-
bated at 37 C in humidiﬁed 95% air and 5% CO2. After 24 h, any
buoyant MEFs were discarded by washing with DPBS, and the basic
medium over the attached MEFs was refreshed. Thereafter, the
basic medium was replaced every two days. When 90% conﬂuence
was reached, the cells were dissociated from the culture dish using
0.05% trypsin-EDTA and frozen in liquid N2 until use.
2.3. Construction of enhanced green ﬂorescent protein (EGFP)-
encoding episomal vector
A transcript of EGFP from pEGFP-N1 (Clontech, Mountain View,
CA, USA) was synthesized using the polymerase chain reaction
(PCR) with a forward primer containing an NheI site (5’ GCTAGC
ATGGTGAGCAAGGGCGAGGAG 3’) and a reverse primer containing a
BamHI site (5’ GGATCC GGCTGATTATGATCTAGAGTCGCGG 3’) under
the following conditions: 5 min at 94 C for initial denaturation,
followed by 35 cycles of 30 s at 94 C, 1 min at 62 C, 30 s at 72 C,
and 10 min at 72 C for the ﬁnal extension. The ampliﬁed products
were fractionated by electrophoresis on an agarose gel and
extracted using the FavorPrep™ GEL/PCR Puriﬁcation Mini Kit
(Favorgen Biotech Co., Ping-Tung, Taiwan). The extracted DNA was
then ligated into TA vectors (RBC, New Taipei city, Taiwan).Transformation of Escherichia coli (E. coli) DH5a (Enzynomics,
Daejeon, Korea), using the EGFP-inserted TA vectors, was con-
ducted in Difco™ LB AGAR (Becton, Dickinson and Co., Franklin
Lakes, NJ, USA) for 16 h at 37 C, and the transformed colonies were
propagated in Difco™ LB Broth (Becton, Dickinson and Co.) for
16 h at 37 C. EGFP-inserted TA vectors were extracted from
competent cells using the FavorPrep™ Plasmid Extraction Mini Kit
(Favorgen Biotech Co.) and digested by NheI and BamHI to separate
EGFP fragments of 762 bp. The EGFP fragments were then ligated,
using T4 ligase (Enzynomics), into the episomal vector pEB-c5
(Addgene, Cambridge, MA, USA), which had been cut by NheI and
BamHI. The resulting EGFP-encoding episomal vector of 11 kb was
then used for the following transfection experiments.
2.4. Preparation of transfection reagent/episomal vector complexes
Complexes of the EGFP-encoding episomal vector with various
transfection reagents were formed following the reagent manu-
facturers’ protocols. Brieﬂy, 1, 2 and 4 ml of Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) or FuGENE HD (Promega, Madison,
WI, USA) were diluted separately in 50 ml of Opti-MEM reduced
serummedium (Gibco Invitrogen, Grand Island, NY, USA), and then
each solution was mixed gently with an equal volume of the same
medium containing 1-mg EGFP-encoding episomal vector. Similarly,
1, 2 and 4 ml of jetPEI (Polyplus, Illkirch, France) were diluted
separately in 50 ml of 150 mM NaCl, and then mixed gently with an
equal volume of 150 mM NaCl containing 1 mg EGFP-encoding
episomal vector. Thus, solutions were obtained containing 1/1, 2/
1 and 4/1 (v/wt) ratios of transfection reagent to EGFP-encoding
episomal vector. After 25 min of complexation time, the com-
plexes were used to transfect the cells, as described below.
2.5. Transfection protocol
A 24-well plate was seeded with 1  105 MEFs and cultured in
basic medium. After reaching 80e90% conﬂuence, the cells were
rinsed with DPBS, and medium was replaced with 400 ml of Opti-
MEM (Gibco Invitrogen). Then, 100 ml of each of the above com-
plex solutions were added to individual wells, overlaying the MEFs
in Opti-MEM. After incubation for 6 h at 37 C in humidiﬁed air,
700 ml of basic medium were added to each well, and the trans-
fected MEFs were cultured for an additional 18 h at 37 C under 5%
CO2 in humidiﬁed air.
2.6. Measurement of cytotoxicity and transfection efﬁciency
At 24 h post-transfection, the transfectedMEFs were dissociated
with 0.05% trypsin-EDTA and suspended in DPBS. Cytotoxicity was
measured using a trypan blue exclusion assay. Brieﬂy, 10 ml of the
cell suspension in DPBSweremixedwith 10 ml of 0.4% (wt/v) trypan
blue solution (SigmaeAldrich, St. Louis, MO, USA), loaded into a
hemocytometer, and examined immediately under a microscope.
Cytotoxicity was calculated as the percentage of cells that were
unstained. To measure the transfection efﬁciency, the transfected
MEFs were transferred to a ﬂow cytometry tube, and the EGFP-
positive cells were detected using FACSCalibur (Becton, Dickinson
and Co.). Data analysis was performed using BD CellQuest Pro
software (Becton, Dickinson and Co.).
2.7. Statistical analysis
Statistical analysis of all numerical data was performed using
Statistical Analysis System (SAS) software (SAS Institute Inc., Cary,
NY, USA). The differences between effects and among groups were
compared using a general linear model procedure, followed by a
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deemed to indicate statistical signiﬁcance.
3. Results
3.1. Effects of Lipofectamine 2000/episomal vector (L/E) ratio on
cytotoxicity and transfection efﬁciency
Cell viability exceeded 90% when the transfection reagent used
was Lipofectamine 2000, regardless of its relative concentration.
Increasing the L/E ratio did not signiﬁcantly increase the cytotox-
icity, and no cytotoxicity (cell viability ¼ 100%) was detected when
the L/E ratio was 4 (Fig. 1A). This ratio also gave the highest yield of
transfection (8.88 ± 1.14%) (Fig. 1B), although the yields at the other
ratios were not signiﬁcantly lower. Thus, an L/E ratio of 4 was the
optimized ratio for delivery of the episomal vector into the cyto-
plasm using Lipofectamine 2000.
3.2. Effects of FuGENE HD/episomal vector (F/E) ratio on
cytotoxicity and transfection efﬁciency
As shown in Fig. 2A, there was no signiﬁcant difference in
cytotoxicity for the various concentrations of FuGENE HD, and at an
F/E ratio of 4 the cell viability was 100%. The transfection yield also
increased with increasing F/E ratio, and signiﬁcantly the best
transfection efﬁciency (12.35 ± 0.75%) was observed at an F/E ratio
of 4 (Fig. 2B). Thus, an F/E ratio of 4 was the optimized ratio for
delivery of the episomal vector into the cytoplasm using FuGENE
HD.
3.3. Effects of jetPEI/episomal vector (J/E) ratio on cytotoxicity and
transfection efﬁciency
Although the differences in cell viability at different J/E ratios
were not statistically signiﬁcant, nevertheless at a J/E ratio of 1 or 2
there was no cytotoxicity (cell viability ¼ 100%), while the highest
cytotoxicity (cell viability¼ 91.67±11.79%) occurred at a J/E ratio of 4
(Fig. 3A). The transfection efﬁciency at a J/E ratio of 2 (13.41 ± 0.36%)
or 4 (13.75 ± 0.88%) was signiﬁcantly greater than at a J/E ratio of 1Fig. 1. Cytotoxicity and transfection efﬁciency of Lipofectamine 2000 as a deliverer of episom
coding for enhanced green ﬂuorescent protein (EGFP) were complexed with Lipofectamine 2
medium, with an equal volume of medium containing 1-mg EGFP-encoding episomal vector.
(L/E ratio) were obtained. MEFs were incubated with these complexes for 6 h in reduced seru
staining, and the transfection efﬁciency was determined, using ﬂow cytometry, by measur
toxicity and transfection efﬁciency, as a function of the L/E ratio, were not statistically signiﬁ
the L/E ratio was 4. Shown are the means ± standard deviation (s.d.) of three independent(9.5 ± 0.38%) (Fig. 3B). Thus, the highest transfection efﬁciency with
the least cytotoxicity occurred at a J/E ratio of 2, suggesting that this
was the optimized ratio for delivery of the episomal vector into the
cytoplasm using jetPEI.
3.4. Comparison of commercial transfection reagents optimized for
delivery of episomal vectors into primary cells
We compared the transfection efﬁciency and cytotoxicity of the
transfection reagent/episomal vector complexes derived from the
Lipofectamine 2000, FuGENE HD and jetPEI at their optimum ratios
(L/E ¼ 4, F/E ¼ 4 and J/E ¼ 2). None of the transfection reagent/
episomal vector complexes showed any cytotoxicity at these opti-
mized ratios (cell viability¼ 100%) (Fig. 4A). As shown in Fig. 4B, the
Lipofectamine 2000/episomal vector complex gave the lowest
transfection yield, even at its optimized ratio (L/E ¼ 4), while the
jetPEI/episomal vector complex gave the highest transfection yield
at its optimized ratio (J/E ¼ 2). Statistically, there was no signiﬁcant
difference in the transfection yields of the complexes derived from
jetPEI and FuGENE HD at their respective optimized ratios. These
results demonstrate that jetPEI at a J/E ratio of 2 is effective for
delivering episomal vectors into the cytoplasm without any
cytotoxicity.
4. Discussion
While electroporation as a method of transfection has a number
of drawbacks, we showed that complexing commercial transfection
reagents with episomal vectors can provide a highly efﬁcient
method of delivering the episomal vectors into the cytoplasm of
primary cells with no cytotoxicity. We observed the highest
transfection efﬁciency using complexes derived from combining
2-ml jetPEI with 1-mg episomal vector.
In previous studies, Lipofectamine-mediated transfection of
swine kidney epithelial cells with episomal vectors gave a 20e30%
transfection yield [27], and FuGENE 6-mediated transfection of hu-
man embryonic stem cells with episomal vectors gave a 30e40%
transfection yield [10]. In both of these cases, an immortalized cell
linewas used. As shown in Fig. 4, Lipofectamine 2000-, FuGENEHD-al vectors into the cytoplasm of mouse embryonic ﬁbroblasts (MEFs). Episomal vectors
000 by gently mixing 1, 2 or 4-ml Lipofectamine 2000, diluted to 50 ml of reduced serum
Thus, complexes with three different ratios of Lipofectamine 2000 to episomal vectors
m medium. At 24 h post-transfection, the cell viability was estimated using trypan blue
ing the percentage of cells that were EGFP positive. Although the differences in cyto-
cant, the lowest cytotoxicity (A) and highest transfection yield (B) were observed when
experiments.
Fig. 2. Cytotoxicity and transfection efﬁciency of FuGENE HD as a deliverer of episomal vectors into the cytoplasm of mouse embryonic ﬁbroblasts (MEFs). Episomal vectors coding
for enhanced green ﬂuorescent protein (EGFP) were complexed with FuGENE HD by gently mixing 1, 2 or 4-ml FuGENE HD diluted to 50 ml of reduced serum medium, with an equal
volume of medium containing 1 mg EGFP-encoding episomal vector. Thus, complexes with three different ratios of FuGENE HD to episomal vectors (F/E ratio) were obtained. MEFs
were incubated with these complexes for 6 h in reduced serum medium. At 24 h post-transfection, the cell viability was estimated using trypan blue staining, and the transfection
efﬁciency was determined, using ﬂow cytometry, by measuring the percentage of cells that were EGFP positive. No signiﬁcant difference was observed in the cytotoxicity at various
F/E ratios. However, the highest transfection efﬁciency, observed when the F/E ratio was 4, was statistically signiﬁcant. Shown are the means ± standard deviation (s.d.) of three
independent experiments. *,**p < 0.05.
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vectors gave only an 8e13% transfectionyield. Thus, the transfection
of primary cells with episomal vectors under our conditions
occurred with much less efﬁciency than comparable transfection of
immortalized cell lines. This observation is consistent with reports
that, regardless of the transfectionprotocol, delivery of DNA into the
cytoplasm of primary cells occurs with low efﬁciency (1e45%)
[28,29].
It is possible that the promoters usedwithin the episomal vector
were unsuitable for primary MEFs, resulting in a low expression of
the episomal vector in the MEFs and concomitant low transfection
efﬁciency. Indeed, previous studies have shown that promoter
activity is dependent on the cell type [30]. Although the cyto-
megalovirus (CMV) promoter used in this study has been usedFig. 3. Cytotoxicity and transfection efﬁciency of jetPEI as a deliverer of episomal vectors in
enhanced green ﬂuorescent protein (EGFP) were complexed with jetPEI by gently mixing 1, 2
containing 1-mg EGFP-encoding episomal vector. Thus, complexes with three different ratios
complexes for 6 h in reduced serum medium. At 24 h post-transfection, the cell viability wa
using ﬂow cytometry, by measuring the percentage of cells that were EGFP positive. No cyto
transfection efﬁciency was observed when the J/E ratio was 2 or 4. Shown are the means ±routinely for inducing strong in vitro and in vivo expression of
transgenes in mammalian cells [31], it may be an inappropriate
promoter for strong vector expression in MEFs. Therefore, future
studies will attempt to improve the efﬁciency with which MEFs are
transfected with episomal vectors by using other promoters, such
as elongation factor-1a, CMV enhancer/chicken b-actin promoter,
or phosphoglycerate kinase.
In conclusion, without need of electroporation equipment, one
can easily and effectively deliver episomal vectors into the cyto-
plasm of primary cells using commercial transfection reagents.
Under our conditions, the transfection efﬁciency was greatest when
the episomal vector was complexed with jetPEI at a J/E ratio of 2.
Although additional studies are needed to improve the transfection
yield, this episomal vector transfection system will provide a basisto the cytoplasm of mouse embryonic ﬁbroblasts (MEFs). Episomal vectors coding for
or 4-ml jetPEI, diluted to 50 ml of 150 mM NaCl, with an equal volume of 150 mM NaCl
of jetPEI to episomal vectors (J/E ratio) were obtained. MEFs were incubated with these
s estimated using trypan blue staining, and the transfection efﬁciency was determined,
toxicity was observed when the J/E ratio was 1 or 2. The statistically signiﬁcant highest
standard deviation (s.d.) of three independent experiments. *p < 0.05.
Fig. 4. Comparison of cytotoxicity and transfection efﬁciency of complexes derived from three commercially available transfection reagents. Episomal vectors coding for enhanced
green ﬂuorescent protein (EGFP) were complexed with Lipofectamine 2000, FuGENE HD, or jetPEI by gently mixing, respectively, 4-ml Lipofectamine 2000, 4-ml FuGENE HD or 2-ml
jetPEI, diluted to 50 ml of reduced serum medium or 150 mM NaCl, with an equal volume of medium or 150 mM NaCl containing 1-mg EGFP-encoding episomal vector. MEFs were
incubated with these complexes for 6 h in reduced serum medium. At 24 h post-transfection, the cell viability was estimated using trypan blue staining, and the transfection
efﬁciency was determined, using ﬂow cytometry, by measuring the percentage of cells that were EGFP positive. No cytotoxicity was observed for any of the complexes. However, the
transfection efﬁciency was signiﬁcantly higher for the complexes derived from FuGENE HD and jetPEI than those derived from Lipofectamine 2000, with the highest transfection
efﬁciency observed with the jetPEI complexes. Shown are the means ± standard deviation (s.d.) of three independent experiments. *p < 0.05.
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of external genes into the chromosomes.
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